References in periodicals archive ?
A pathogen reduction technology licensed in the United States for transfusible plasma and apheresis platelets (INTERCEPT Blood System, Cerus Corporation, Concord, California) is effective in inactivating Zika virus as assessed by in vitro infectivity assays (>6.5 [log.sub.10] in plasma).